On May 31, 2017, we signed a Technology Assignment Agreement with the University of British Columbia whereby we retain sole worldwide rights to all patents emergent from the technology under developm…
we entered into a separate process development collaboration by way of a Master Service Agreement with the Almac Group (UK)(“Almac”), a seasoned GMP pharmaceutical CDMO
these financial institutions, there can be no assurance that there will not be additional bank failures or issues in the broader financial system. Likewise, there is no guarantee that any of the U.S.…
Reciprocal relationship from FISI graph: Reciprocal relationship from INM graph: these financial institutions, there can be no assurance that there will not be additional bank failures or issues in t…
these financial institutions, there can be no assurance that there will not be additional bank failures or issues in the broader financial system. Likewise, there is no guarantee that any of the U.S.…
Reciprocal relationship from FISI graph: Reciprocal relationship from INM graph: these financial institutions, there can be no assurance that there will not be additional bank failures or issues in t…
y results from the Phase 2 clinical trial (755-201-EB) for the treatment of symptoms in patients with EB. Rare Cannabinoid Products in the Health and Wellness Sector BayMedica has a revenue-generatin…
perience. Expected credit losses on our accounts receivable were $0 and $ 66,775 as at June 30, 2024 and 2023 respectively. We had $ 66,775 and $ 0 of write-offs during the year ended June 30, 2024 a…
s this group of individuals that will help optimize our chances for success. Scope of research and robust pharmaceutical pipeline Over several years of dedicated research, InMed has built a robust pi…
ed in the determination of research & development accruals. Actual results could differ from those estimates. Basis of Consolidation These consolidated financial statements include the accounts of th…
InMed Pharmaceuticals Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
INM-DEBT
Debt stack $420,147
90%
Market cache reports total debt of $420,147.
INM-DEBT-10289
Warrants outstanding: 700
90%
xbrl warrant detail from xbrl 2025-06-30.
InMed Pharmaceuticals Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for InMed Pharmaceuticals Inc..
InMed Pharmaceuticals Inc. Ownership
No ownership data on recordNo major institutional ownership relationships found in our database for InMed Pharmaceuticals Inc..
InMed Pharmaceuticals Inc. Extended Supply Chain Network
